49 results
SC 14D9
PNT
POINT Biopharma Global Inc.
13 Oct 23
Tender offer solicitation
7:11am
of the applicable performance goals. In addition, POINT may, prior to the Effective Time, amend each these awards to provide that if the holder is terminated … and Current Reports on Form 8-K. In addition, the Projections may be affected by POINT’s ability to achieve strategic goals, objectives and targets over
SC14D9C
EX-99.2
PNT
POINT Biopharma Global Inc.
3 Oct 23
Written communication relating to third party tender offer
5:24pm
committees and activities will continue as planned.
What changes will be made to the current POINT organizational structure or corporate goals?
Integration … planning is in process, and we expect further clarity in the coming weeks. We will continue to be focused on our 2023 corporate goals
ARS
2022 FY
PNT
POINT Biopharma Global Inc.
1 May 23
Annual report to shareholders
1:52pm
may not achieve research, development and commercialization goals in the time frames that we publicly estimate. ◦ We may be unable to obtain regulatory … that hope to enhance the safety of actinium-based radioligands, the goals of our tumor microenvironment targeting prodrug platform extend beyond 225Ac
DEF 14A
zcij02ulpz7l
28 Apr 22
Definitive proxy
8:36am
424B3
8hrl3ei
31 Mar 22
Prospectus supplement
11:42am
POS AM
g4ghj26eqm
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
EX-10.4
sgs4i4rg3n6m
12 Nov 21
Prospectus supplement
8:41am
424B3
EX-10.2
n5d54 j44skbavy
12 Nov 21
Prospectus supplement
8:41am
424B3
stgpsi3i bz6ay79bbet
5 Aug 21
Prospectus supplement
4:26pm
8-K
EX-10.3
pb2 4rmfv66oys4og7
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am
424B3
z1xonz0
9 Jun 21
Prospectus supplement
4:42pm